Sign in

You're signed outSign in or to get full access.

Cyanotech - Q1 2025

August 8, 2024

Transcript

Matt Custer (CEO)

Aloha from Kona, Hawaii. Thank you all for joining us today to report Cyanotech's first quarter fiscal year 2025 earnings results. I am Matt Custer, President and Chief Executive Officer of Cyanotech. Joining me on the call today is Felicia Ladin, our Chief Financial Officer. I will turn the call over to Felicia to provide our forward-looking statement.

Felicia Ladin (CFO)

Thanks, Matt. Our discussion today may include forward-looking statements. We do not undertake any obligation to update forward-looking statements, either as a result of new information, future events, or otherwise. Our actual results may differ materially from what is described in these forward-looking statements. Some of the factors that may cause results to differ are listed in our publicly filed documents. For additional information, we encourage you to review our 10-Q and fiscal year 2024 10-K report filed with the Securities and Exchange Commission. I'll turn it back to Matt for comments on the quarter. Matt?

Matt Custer (CEO)

This quarter's net sales increased 15% as compared to prior year, primarily due to increased sales of astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina gummies in May to complement the astaxanthin gummy product. Our growth in sales for the quarter was offset by lower gross profit. Production has been at a low for the trailing six quarters, resulting in higher costs, which resulted in the gross profit decline. This strategic production management has allowed us to manage both spending and inventory to mitigate cash outflow. Now, we turn our focus to meeting this changing demand with a well-managed increase in supply. We have preliminarily secured the financing to ensure we can meet the market demand.

We feel positive about the future of our brand and the consumer's interest in sustainable, high-quality dietary supplements. Turning over the call to Felicia to discuss the financial results. Felicia?

Felicia Ladin (CFO)

Thank you, Matt, and good evening, everyone. Key financial results for the first quarter. Total net sales for the first quarter of fiscal 2025 were $5.9 million, compared to $5.1 million for the first quarter of fiscal 2024. Total sales revenue increased by $800,000 or 15% from prior year. Gross profit for the first quarter of fiscal 2025 was $1.5 million, with a gross profit margin of 25%, compared to gross profit of $1.5 million and a gross profit margin of 29.8% in the first quarter of fiscal 2024. A 4.8 percentage point decrease due to higher costs related to lower production volumes, as Matt noted.

Operating loss for the first quarter was $1 million, compared to operating loss of $1.2 million in the first quarter of fiscal 2024, a decrease of $200 thousand. Net loss for the current quarter was $1.2 million or 17 cents per diluted share, compared to net loss of $1.4 million or 22 cents per diluted share in the prior year. The company had cash of $720 thousand and working capital of $207 thousand, compared to $707 thousand and $2 million, respectively, as of March 31, 2024. The drop in working capital is due to lower inventory, higher accounts payable, and a reclassification of $1 million of debt from long-term to short-term. I will hand the call back to Matt for concluding comments. Matt?

Matt Custer (CEO)

We've had no questions. Thank you for attending the call. Aloha.